LMRI

ANALYST NOTE: LMRI (Lumexa Imaging Holdings, Inc.) Date: 2026-06-20 Current Price: $9.41

1. Structural Readiness

State: Context-Only Conservative Entry: — Breakout Level: — Extension: — ATR Current: 7.3% (Very High)

Analysis:

2. Thesis Layer

Thesis Status: Tactical / Setup-Led Macro Thesis: None Named

At this date, LMRI is classified as a TACTICAL, setup-led name. There is no named secular macro thesis attached to this specific setup in the current evidence base. The investment case must be judged strictly on the quality of the technical setup (once formed) and the underlying business fundamentals. No external macro drivers (e.g., specific regulatory shifts, interest rate pivots) are explicitly cited as the primary catalyst for this specific trade setup. The conviction stack relies entirely on the structural readiness of the price action and the strength of the company's operational execution as reported by management.

3. The Business

Company Overview: Lumexa Imaging Holdings, Inc. operates as a network of diagnostic outpatient imaging centers in the United States. The company generates revenue by providing diagnostic imaging services (scans) and physician interpretation services (reads) to patients within these centers.

Business Model & Structure:

• Network Composition: The company operates 86 imaging centers ("JV centers") through joint ventures with health system partners. It also utilizes a network of unconsolidated affiliates.
• Referral Base: As of the 2025 year-end reporting, the company has built a diversified network of approximately 102,000 referring physicians across more than 32,000 physician practices.
• Growth Strategy: The company pursues a dual-growth strategy of organic expansion (de novo centers) and inorganic growth (acquisitions).
• De Novo Economics: Management states that new centers require an average initial capital investment of $4.0 million, targeting annual Adjusted EBITDA contributions of $1.0 million to $3.0 million.
• Ramp Profile: Center-level ramp to profitability can be as short as 12 months, with maturity reached in 24 months. Some centers have reached profitability in as little as six months.
• Recent Activity: In the first half of 2026, the company completed 2 acquisitions and opened 2 de novo centers. Management guidance indicates a goal of opening 8 to 10 de novo centers for the full year.

Financial Performance (PIT Data):

• Revenue Growth: Consolidated revenue grew 7.8% year-over-year, reaching $1.023 billion for the year ended December 31, 2025 (up from $948.9 million in 2024). System-wide revenue grew 8.2%.
• Profitability: For the year ended December 31, 2025, the company reported a net loss of $47.1 million but generated Adjusted EBITDA of $230.2 million, representing an Adjusted EBITDA margin of 22.5%.
• Guidance (as of May 12, 2026): Management expects full-year revenue between $1.045 billion and $1.097 billion and Adjusted EBITDA between $234 million and $242 million.
• Capital Structure: The company completed an IPO on December 12, 2025, raising $462.5 million in gross proceeds. Net proceeds of $406.4 million were used to pay down outstanding borrowings. The refinancing term loan requires quarterly principal payments of $2.1 million.

Operational Highlights:

• Advanced Modalities: Q1 2026 saw advanced modalities grow 7% year-over-year, with PET growing 23.1% and MRI growing 8.2%.
• Technology Adoption: The company is advancing site planning with UPMC and expects to announce several new de novo sites with them in 2026. Additionally, the rollout of an AI-powered breast arterial calcification solution is continuing with strong patient uptake.
• Fleet Modernization: The company is on track to have 66% to 67% of its MRI fleet equipped with FastScan technology by year-end 2026 (up from 51% at the start of the year).

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector The company fits the archetype of a Growth Leader with Margin Inflector characteristics. The business model is designed to scale EBITDA through the addition of high-margin de novo centers and the optimization of existing assets via technology upgrades (FastScan, AI solutions). The 22.5% Adjusted EBITDA margin and the clear path to profitability for new centers support this classification.

Conviction Stack:

• Thesis Strength: Moderate. The business fundamentals are strong (double-digit revenue growth, high EBITDA margins), but the setup is purely tactical with no named macro thesis.
• Evidence Quality: High. The evidence base is robust, containing specific financial figures, management guidance, and operational metrics from both SEC filings and earnings transcripts dated within the last quarter.
• Structural Quality: Unknown/Neutral. The structural setup is currently undefined. The "Forming" or "Confirmed" status cannot be determined without price action data relative to pivot levels.
• Setup Readiness: Low. The setup is in a "context-only" state. The current price of $9.41 is not yet actionable as a breakout or a confirmed pullback entry.
• Rerating Potential: Dependent on the successful execution of the 8-10 de novo goal and the continued expansion of advanced modalities. The market may re-rate the stock if the company demonstrates consistent EBITDA growth and a path to GAAP profitability, but this is contingent on the setup forming.

Volatility Context:

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Operational Execution: Confirmation that the 8-10 de novo goal is met or exceeded, and that the UPMC partnership yields announced sites.
• Margin Expansion: Continued improvement in Adjusted EBITDA margins beyond the 22.5% reported in 2025.

What Would Invalidate the Case:

• Execution Failure: Missing the 8-10 de novo target or failing to achieve the projected EBITDA guidance ($234M-$242M).
• Debt Servicing Issues: Inability to meet the $2.1 million quarterly principal payments or a deterioration in the balance sheet post-IPO.

Gaps in Evidence:

• GAAP Profitability: While Adjusted EBITDA is strong, the company reported a net loss of $47.1 million in 2025. The timeline to GAAP profitability is not explicitly detailed in the provided evidence, only the ramp to center-level profitability.
• Market Sentiment: No data is provided on short interest, institutional ownership changes, or relative strength compared to the sector.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key evidence: Revenue grew 7.8% to $1.023B with 22.5% EBITDA margin; Management guidance for 8-10 de novo centers is clear; IPO proceeds used to deleverage balance sheet. Key risks: Current price action shows no defined structural setup (context-only); Very high ATR (7.3%) indicates elevated volatility and sizing risk; Net loss of $47.1M persists despite strong EBITDA. Expected path: Management expects to open 8-10 de novo centers and expand AI solutions; structural setup must form before capital deployment. Expected horizon: 3-6 months for setup formation and execution of de novo openings.